SOUTH SAN FRANCISCO, Calif. — August 7, 2025 — Leads & Copy — CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced its second quarter 2025 financial results and provided a business update. The company reported positive initial clinical results for CX-2051 in advanced colorectal cancer and completed a $100 million underwritten offering of common stock.
Key pipeline program updates include the initiation of CX-2051 dose expansions and planning for a Phase 2 study in advanced CRC in 1H 2026. Phase 1 dose escalation of CX-801 in combination with KEYTRUDA® was initiated in May 2025, with initial clinical data anticipated in 2026.
Financially, CytomX ended Q2 2025 with $158.1 million in cash, cash equivalents, and investments, expected to last until Q2 2027. Total revenue for the quarter was $18.7 million, with operating expenses at $19.9 million.
The company also presented preclinical data for an mRNA encoded masked IL-12 molecule in collaboration with Moderna at the AACR Annual Meeting.
Chris Ogden, SVP, Chief Financial Officer, cogden@cytomx.com
Stephanie Ascher, Precision AQ (formerly Stern Investor Relations), Stephanie.Ascher@precisionaq.com
Teri Dahlman, Redhouse Communications, teri@redhousecomms.com
Source: CytomX Therapeutics, Inc.
